PH-responsive dual pulse multiparticulate dosage form for treatment of rheumatoid arthritis

Drug Development and Industrial Pharmacy

Volumn 36, Issue 11, 2010, Pages 1295-1302

  Lotlikar, Vishwanath ^a   Kedar, Uttam ^a   Shidhaye, Supriya ^b   Kadam, Vilasrao ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

^b Vivekanand Education Society's College of Pharmacy   (India)

Author keywords

Eudragit ; Extrusionspheronization; Ketoprofen; Lag time; Multiple unit; Pulsatile release; Rheumatoid arthritis

Indexed keywords

EUDRAGIT; KETOPROFEN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PELLET; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; PARTICLE SIZE; PELLET EXTRUSION; PH; PULSATILE DRUG RELEASE; RHEUMATOID ARTHRITIS; SPHERONIZATION; SURFACE PROPERTY;

ACRYLIC RESINS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DELAYED-ACTION PREPARATIONS; DRUG CHRONOTHERAPY; EXCIPIENTS; GASTROINTESTINAL TRACT; HYDROGEN-ION CONCENTRATION; KETOPROFEN; PARTICLE SIZE; POLYMETHACRYLIC ACIDS; PULSE THERAPY, DRUG; SOLUBILITY; TIME FACTORS;

EID: 77956909561     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639041003786185     Document Type: Article

References (23)

1. Tiwari S, Rajabi-Siahboomi A. (2008). Extended-release oral drug delivery technologies: Monolithic matrix systems. In: Jain K, ed. Drug delivery systems. New York: Humana Press, 217-218
2. Gurny R, Junginger H, Peppas N. (1993). Pulsatile drug delivery: Current application and future trends. Germany: Wissenschaftliche Verlagsgesellschaft, 36.
3. Khan Z, Pillay V, Choonara Y, Toit L. (2009). Drug delivery technologies for chronotherapeutic applications. Pharm Dev Technol, http://informahealthcare. com/doi/abs/10.3109/1083745 0902922736 [accessed April 13, 2010].
4. Cutolo M, Masi A. (2005). Circadian rhythms and arthritis. Rheum Dis Clin North Am, 31(1):115-129
5. Villaggio B, Cutolo M, Otsa K, Aakre O, Sulli A, Seriolo B. (2005). Altered circadian rhythms in rheumatoid arthritis patients play a role in the diseases symptoms. Autoimmun Rev, 4(8):497-502.
6. Dollery C. (1999). Therapeutic drugs (K18-K20), vol.1. Edinburgh, Scotland: Churchill Livingstone.
7. Sweetman, SC, ed. (2005). Martindale: The complete drug reference. London: Pharmaceutical Press, 51.2.
8. Shavi G, Nayak U, Averineni R, Arumugam K, Meka S, Nayanabhirama U, et al. (2003). Multiparticulate drug delivery system of aceclofenac: Development and in vitro studies. Drug Dev Ind Pharm, 35:252-258
9. Ghebre-sallassie I. (1989). Evaluation and characterization of pellet. In: Pharmaceutical pelletization technology. New York: Informa HC, 261.
10. Sadeghi F, Akhagari A, Garekani H. (2006). Combination of time-dependent and pH-dependent polymethacrylates as a single coating formulation for colonic delivery of indomethacin pellets. Int J Pharm, 320:137-142
11. Serajuddin A, Rosoff M. (2006). pH-solubility profile of papaverine hydrochloride and its relationship to the dissolution rate of sustained-release pellets. J Pharm Sci, 73(9):1203-1208
12. Jain S, Chourasia H. (2004). Design and development of multiparticulate system for targeted delivery to colon. Drug Deliv, 11:201-207
13. Pawar A, Sharma S. (2006). Low density multiparticulate system for pulsatile release of meloxicam. Int J Pharm, 313:150-158
14. Bansal A, Kakumanu V, Shah B. (2006). Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci, 95:1641-1665
15. Mura P, Manderioli A, Bramanti G, Furlanetto S, Pinzauti S. (1995). Utilization of differential scanning calorimetry as a screening technique to determine the compatibility of ketoprofen with excipients. Int J Pharm, 119(1):71-79
16. Sajeev C, Jadhav P, RaviShankar D, Saha R. (2002). Determination of flurbiprofen in pharmaceutical formulations by UV spectrophotometry and liquid chromatography. Anal Chim Acta, 463(2):207-217 (Pubitemid 34722334)
17. Bodmeier R, Schmidt C. (2001). A multiparticulate drug delivery system based on pellets incorporated into congealable polyethylene glycol carrier material. Int J Pharm, 216:9-16.
18. Shivkumar H, Suresh S, Desai B. (2006). Design and evaluation of pH sensitive multiparticulate system for chronotherapeutic delivery of diltiazem hydrochloride. Indian J Pharm Sci, 68:781-787 (Pubitemid 46457279)
19. Ozeki Y, Ando M, Watanabe Y, Danjo K. (2004). Time-programmed pulsatile release of dextran from calcium-alginate gel beads coated with carboxy-n-propylacrylamide copolymers. J Control Release, 80(1-3):57-68.
20. Gohel MC, Parikh RK, Brahmbhatt BK, Shah AR. (2000). Improving the tablet characteristics and dissolution profile of ibuprofen by using a novel coprocessed superdisintegrant: A technical note. AAPS PharmSciTech, 8(1):E94-9.
21. Rani M, Mishra B. (2004). Comparative in vitro and in vivo evaluation of matrix, osmotic matrix, and osmotic pump tablets for controlled delivery of diclofenac sodium. AAPS PharmSciTech, 5(4):e71, article 71.
22. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut, 29(8):1035-1041
23. Corrigon O, Devlin Y, Butlar J. (2003). Influence of dissolution medium buffer composition on ketoprofen release from ER products and in vitro-in vivo correlation. Int J Pharm, 254:147-154